What Happened
New data from The Hackett Group, as reported by CFO.com, revealed that the pharmaceutical industry's cash conversion cycle extended to nearly 186 days in 2025. This lengthening reflects increased working capital tied up as companies ramped up investments in biologics and glucagon-like peptide-1 (GLP-1) therapies, which have seen rapid market growth. The extended cash conversion cycle indicates that pharma firms are taking longer to convert their investments in inventory and receivables back into cash.
Why This Matters
For credit and capital markets professionals, the elongation of the cash conversion cycle in pharma signals tighter liquidity conditions within the sector, potentially affecting short-term financing needs and credit profiles. The surge in investment related to the GLP-1 boom underscores a strategic shift toward biologics, which typically require longer development and production timelines, thus increasing working capital demands. This dynamic may influence lenders' and investors' risk assessments of pharmaceutical companies, particularly in terms of funding working capital and managing cash flow volatility. Understanding these trends is crucial for anticipating credit market behavior and capital allocation within the healthcare sector amid evolving innovation cycles.